The company will invest $1.2bn over the next four years to expand and upgrade its manufacturing capacity for pre-fillable syringes and advanced drug delivery systems across seven manufacturing facilities.

2019 saw fewer revenue-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

The approval of the Ranger paclitaxel-coated balloon makes Boston Scientific the only company offering both a drug-eluting stent and drug-coated balloon for treating peripheral artery disease in the US.

Execs from Merck, Pfizer, Bristol, Abbvie and smaller biopharmas weigh in on how developments in cancer research may benefit other disease areas, especially autoimmune and neurological conditions.